UK markets closed

  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     

  • FTSE 250

    18,928.30
    +20.56 (+0.11%)
     

  • AIM

    809.27
    +3.43 (+0.43%)
     

  • GBP/EUR

    1.1373
    +0.0018 (+0.16%)
     

  • GBP/USD

    1.2332
    -0.0058 (-0.47%)
     

  • Bitcoin GBP

    22,926.29
    -88.56 (-0.38%)
     

  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     

  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     

  • DOW

    33,274.15
    +415.12 (+1.26%)
     

  • CRUDE OIL

    75.70
    +1.33 (+1.79%)
     

  • GOLD FUTURES

    1,987.00
    -10.70 (-0.54%)
     

  • NIKKEI 225

    28,041.48
    +258.55 (+0.93%)
     

  • HANG SENG

    20,400.11
    +90.98 (+0.45%)
     

  • DAX

    15,628.84
    +106.44 (+0.69%)
     

  • CAC 40

    7,322.39
    +59.02 (+0.81%)
     

Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023

EQS Group
·2-min read

Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
16.03.2023 / 06:00 GMT/BST

Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET.

 

Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CET with Mauro Ajani, Founder and Chairman, Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the 2022 financial and operating results as well as the next milestones of the company.

 

Live conference call and video webcast presentation:

Date:  Thursday, 23 March 2023
Time:  2:00 pm CET

Webcast link: Chrome (recommended) or Firefox https://media.choruscall.eu/mediaframe/webcast.html?webcastid=L3HNXtf4


Please note that there is a function to type in your questions via webcast.

Via phone:

Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.

Switzerland / Europe

+41 (0) 58 310 50 00

United Kingdom

+44 (0) 207 107 06 13

United States

+1 (1) 631 570 56 13

 

The presentation and media release as well as the Annual Report 2022 will be available for download as of 07:00 am CET on 23 March 2023 at www.cosmopharma.com


Replay

The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.

 

 

Contact:

Hazel Winchester

Head of Investor Relations

Cosmo Pharmaceuticals N.V.

Tel: +353 1 817 03 70

hwinchester@cosmopharma.com


End of Media Release

Language:

English

Company:

Cosmo Pharmaceuticals N.V.

Riverside 2, Sir John Rogerson’s

Dublin 2 Dublin

Ireland

Phone:

+ 353 1 817 0370

E-mail:

info@cosmopharma.com

Internet:

https://www.cosmopharma.com/

ISIN:

NL0011832936

Listed:

SIX Swiss Exchange

EQS News ID:

1583775


 

End of News

EQS News Service

show this
show this

Latest stories

  • How Credit Suisse lured – and then burned – the Saudi crown prince

    When Credit Suisse opened its first office in Saudi Arabia in early 2021, Bruno Daher, the cigar-smoking head of Credit Suisse’s Middle East business, declared it a “key growth market”.

  • Cash Isas are paying the highest rates in a decade – here’s why you should ignore them

    Cash Isas are paying the best interest rates for more than a decade – but financial advisers are urging savers to ignore them.

  • Pound surges to become best performing currency this year

    The pound has surged to become the best performing currency among developed economies this year with the Bank of England expected to carry on raising interest rates.

  • Here’s how much I’d need to invest in Lloyds shares for £1,000 a year in passive income

    Lloyds shares remain popular with UK dividend investors. Here I explore how much it would cost to generate £1,000 a year in passive income from them. The post Here’s how much I’d need to invest in Lloyds shares for £1,000 a year in passive income appeared first on The Motley Fool UK.

  • 3 stocks I’d put 100% of my money into

    Investing all of my money into a small handful of stocks is incredibly risky. But if I had to do so, here's the three I would choose. The post 3 stocks I’d put 100% of my money into appeared first on The Motley Fool UK.

  • Are these FTSE 100 shares ready to bounce back?

    Stephen Wright looks at two of the worst-performing shares from the FTSE 100 over the last five years. Is either worth buying for a recovery? The post Are these FTSE 100 shares ready to bounce back? appeared first on The Motley Fool UK.

  • Value hunting after the stock market correction! 3 huge opportunities

    Dr James Fox details three stocks that are trading at discounts following the stock market correction. He believes this is a rare buying opportunity. The post Value hunting after the stock market correction! 3 huge opportunities appeared first on The Motley Fool UK.

  • Bricks, banks, and buildings: 5 dividend stocks to buy in April

    Which dividend stocks should investors be looking to buy in April? Stephen Wright sees opportunities in shares on both sides of the Atlantic. The post Bricks, banks, and buildings: 5 dividend stocks to buy in April appeared first on The Motley Fool UK.

  • London wins just second listing of the year amid stock market exodus fears

    An Australian finance company is gearing up for a £200m London listing in a boost for the City’s beleaguered stock market.

  • Warren Buffett’s advice about what to do when the stock market plunges

    It may be a wise for investors to mimic Warren Buffett’s tactics in these weaker markets, even if stocks plunge by 50% or more. The post Warren Buffett’s advice about what to do when the stock market plunges appeared first on The Motley Fool UK.

  • If I’d invested £500 in NatWest shares 1 year ago, here’s what I’d have now!

    Dr James Fox explores whether an investment in NatWest shares one year ago would have been a shrewd one. The banking stock tanked in March. The post If I’d invested £500 in NatWest shares 1 year ago, here’s what I’d have now! appeared first on The Motley Fool UK.

  • I’d buy this UK stock today for a 7% return

    Stephen Wright thinks that buying stock in a UK insurer can get him a 7% return. And with preferred shares, he’s looking to limit his risk. The post I’d buy this UK stock today for a 7% return appeared first on The Motley Fool UK.

  • The Direct Line share price is testing new lows. Do I sell?

    The Direct Line share price crashed to new lows this week. But after falling more than 50%, are shares in the 38-year-old insurance group now too low? The post The Direct Line share price is testing new lows. Do I sell? appeared first on The Motley Fool UK.

  • Down 57%, will the Scottish Mortgage share price recover in 2023?

    As the Scottish Mortgage share price languishes, Andrew Mackie assesses whether now's the time for him to invest ahead of a new bull market. The post Down 57%, will the Scottish Mortgage share price recover in 2023? appeared first on The Motley Fool UK.

  • Millions face awful April with huge hikes in household bills just as energy scheme ends

    Jump in broadband, mobile, water and council tax will leave households almost £700 a year worse off

  • Branson-backed Virgin Voyages sets sail on quest for new funding

    Sir Richard Branson's cruise-line venture is seeking hundreds of millions of dollars in fresh funding even as the Virgin Group founder faces financial turbulence in other parts of his business empire. Sky News has learnt that Virgin Voyages is in the early stages of plans to raise a substantial sum of money from new and existing investors. The disclosure of Virgin Voyages' talks to secure new capital comes just days after Virgin Orbit, Sir Richard's commercial satellites business, said it would lay off the majority of its staff and cease operations after running out of money.

  • 2 shares to buy before the recovery!

    Dr James Fox details two of his top stocks to buy after the recent stock market correction that saw several sectors, most notably, finance, suffer. The post 2 shares to buy before the recovery! appeared first on The Motley Fool UK.

  • A great opportunity to buy FTSE bank stocks. Even banks can benefit too!

    Dr James Fox explains why the recent correction and current environment have created an inviting opportunity to buy FTSE-listed banking stocks. The post A great opportunity to buy FTSE bank stocks. Even banks can benefit too! appeared first on The Motley Fool UK.

  • How I’d invest £1,000 in the FTSE 100 to build long-term wealth

    Building wealth comes down to buying shares that will be worth more in future than they are today. Which FTSE 100 stocks fit the bill? The post How I’d invest £1,000 in the FTSE 100 to build long-term wealth appeared first on The Motley Fool UK.

  • Best British shares to buy in April

    We asked our writers to share their ‘best of British’ stocks to buy this month, including a double nomination for an Footsie stalwart. The post Best British shares to buy in April appeared first on The Motley Fool UK.